| Author/Treatment | Patients | Prior Treatment | Efficacy Response | Survival | ||||||||||||
| Total No. | Radiation Therapy % | Chemotherapy % | CR | PR | SD | PFS | OS (%) | |||||||||
| Median (mos) | 6 mos | Median (mos) | 1 yr | 2 yrs | 3 yrs | 5 yrs | 10 yrs | |||||||||
| [15] Lashford et al. 2002, Temozolomide | 33 | All | 33 | 0 | 12 | 18 | 4.7 | |||||||||
| [16] Dreyer et al. 2003, Idarubicin | 18 | 88 | 89 | 0 | 5 | 17 | ||||||||||
| [17] Warren et al. 2006, Lobradimil and Carboplatin | 9 | 95 | 60 | 0 | 0 | 0 | ||||||||||
| [18] Fouladi et al. 2007, Tipifarnib | 38 | Recurrent or progressive high-grade gliomasD | 0 | 3 | ||||||||||||
| [19] Gururangan et al. 2010, Bevacizumab and Irinotecan | 18 | All | 0 | 0 | 44 | 4.2 | 42 | |||||||||
| [20] Nicholson et al. 2007, Temozolomide | 23 | 84 | ALL | 0 | 4 | 30 | ||||||||||
| [21] Warren et al. 2012, 06-benzylguanine and temozolomide | 25 | ALL | ALL | 0 | 4 | 16 | 16 | |||||||||
| Burzynski et al. 2014, Antineoplastons A10 and AS2-1 | 15 | 80 | 93 | 13 | 13 | 20 | 6.3 | 53 | 8.4 | 33.3 | 6.7 | 6.7 | 6.7 | 6.7* | ||
| ||||||||||||||||